CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,899,880 | +106.1% | 63,883 | +24.9% | 0.00% | 0.0% |
| Q2 2023 | $921,903 | +181.2% | 51,160 | +150.6% | 0.00% | – |
| Q1 2023 | $327,865 | -12.2% | 20,415 | 0.0% | 0.00% | – |
| Q4 2022 | $373,595 | -6.7% | 20,415 | +0.1% | 0.00% | – |
| Q3 2022 | $400,519 | +3.0% | 20,393 | -2.1% | 0.00% | – |
| Q2 2022 | $388,666 | -1.4% | 20,840 | +16.0% | 0.00% | – |
| Q1 2022 | $394,222 | -37.0% | 17,960 | -18.5% | 0.00% | – |
| Q4 2021 | $626,000 | +47.3% | 22,050 | +9.2% | 0.00% | – |
| Q3 2021 | $425,000 | +3.4% | 20,201 | -7.3% | 0.00% | – |
| Q2 2021 | $411,000 | +55.1% | 21,800 | +25.9% | 0.00% | – |
| Q1 2021 | $265,000 | +9.1% | 17,319 | +0.4% | 0.00% | – |
| Q4 2020 | $243,000 | -5.4% | 17,243 | +5.1% | 0.00% | – |
| Q3 2020 | $257,000 | -12.3% | 16,413 | 0.0% | 0.00% | – |
| Q2 2020 | $293,000 | – | 16,413 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |